Quick Answer
KalVista Pharmaceuticals, Inc. reported Operating Income Loss of -$188.00 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed a decrease of -33.9% in Operating Income Loss from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2013 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: -$1.86 million | Q2 2014: -$2.44 million | Q3 2014: -$3.57 million | Q1 2015: -$4.90 million | Q2 2015: -$5.67 million | Q3 2015: -$4.90 million | Q1 2016: -$3.82 million | Q1 2016: -$6.53 million | Q2 2016: -$6.96 million | Q3 2016: -$5.12 million | Q3 2016: -$2.41 million | Q4 2016: -$4.03 million | Q1 2017: -$8.12 million | Q3 2017: -$5.45 million | Q4 2017: -$5.94 million | Q1 2018: -$4.35 million | Q3 2018: -$7.01 million | Q4 2018: -$4.89 million | Q1 2019: -$6.66 million | Q3 2019: -$9.56 million | Q4 2019: -$9.29 million | Q1 2020: -$12.72 million | Q3 2020: -$14.44 million | Q4 2020: -$12.78 million | Q1 2021: -$12.66 million | Q3 2021: -$19.52 million | Q4 2021: -$23.60 million | Q1 2022: -$26.68 million | Q3 2022: -$26.32 million | Q4 2022: -$25.88 million | Q1 2023: -$26.95 million | Q3 2023: -$29.09 million | Q4 2023: -$29.75 million | Q1 2024: -$33.15 million | Q3 2024: -$44.22 million | Q3 2024: -$43.48 million | Q4 2024: -$45.81 million | Q1 2025: -$42.94 million | Q3 2025: -$59.01 million | Q3 2025: -$46.05 million.
- Over the full 14 years of available data (2013 to 2025), KalVista Pharmaceuticals, Inc.'s Operating Income Loss has declined by 3,504.2%.
- Historical annual values: Fiscal year 2025: -$188.00 million | Fiscal year 2024: -$140.45 million | Fiscal year 2023: -$110.87 million | Fiscal year 2022: -$96.61 million | Fiscal year 2021: -$57.92 million | Fiscal year 2020: -$40.53 million | Fiscal year 2019: -$29.82 million | Fiscal year 2018: -$18.71 million | Fiscal year 2017: -$22.34 million | Fiscal year 2016: -$15.18 million | Fiscal year 2015: -$21.04 million | Fiscal year 2015: -$8.09 million | Fiscal year 2014: -$11.68 million | Fiscal year 2013: -$5.22 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: